Immunotherapy and infection specialist BioNTech SE (Mainz, Germany) has acquired preclinical and clinial antibody assets and infrastructior from MabVax Therapeutics Holding, Inc.

Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.

Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized.  But success relies on following a plan from the start — learn how in this free whitepaper

With partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.

The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.

LEA, the Lipidomics Excellence Award, was founded to strengthen life sciences through lipidomics.  Over the course of April, the LEA jury deliberated on the submitted projects to announce the three LEA awardees.

US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).

The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.

Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgène’s armed oncolytic immunotherapies.

Liver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.